Royal Bank of Canada Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $131.00
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price increased by Royal Bank of Canada from $130.00 to $131.00 in a research report report published on Friday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other research analysts have also weighed in on AXSM. Mizuho reiterated a buy […]
More Stories
News from the WHO: Types of data requested to inform December 2024 COVID-19 vaccine antigen composition deliberations https://ift.tt/NUaBW5H October 07, 2024 at 07:00AM
Published on October 07, 2024 at 07:00AM View on website
‘It’s Our Hurricane Katrina’: Asheville Residents Describe Death, Destruction, Danger After Hurricane Helene
By Arjun Singh ASHEVILLE. N.C.—Tunnel Road is a major thoroughfare between Asheville and the Swannanoa Valley in western North Carolina....
California Faces Wave of Lawsuits Over Gender Identity Notification in Schools
By Brad Jones A mother’s tears of worry and frustration over her 17-year-old daughter’s secret social gender transition at school...
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.56
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty ratings...
Lennar Co. (LEN) to Issue Quarterly Dividend of $0.50 on October 24th
Lennar Co. (NYSE:LEN – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports. Shareholders of record...
Industria de Diseño Textil, S.A. (OTCMKTS:IDEXY) Plans Dividend of $0.29
Industria de Diseño Textil, S.A. (OTCMKTS:IDEXY – Get Free Report) announced a dividend on Saturday, October 5th, NASDAQ reports. Investors...